Harmony Operating Margin from 2010 to 2025

HRMY Stock  USD 32.99  1.25  3.65%   
Harmony Biosciences Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin is likely to outpace its year average in 2025.
Check Harmony Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harmony Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 48.6 M, Net Interest Income of 1.1 M or Depreciation And Amortization of 16.4 M, as well as many indicators such as Price To Sales Ratio of 2.6, Dividend Yield of 0.0 or PTB Ratio of 3.12. Harmony financial statements analysis is a perfect complement when working with Harmony Biosciences Valuation or Volatility modules.
  
Check out the analysis of Harmony Biosciences Correlation against competitors.

Latest Harmony Biosciences' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Harmony Biosciences Holdings over the last few years. It is Harmony Biosciences' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harmony Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.28 %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Harmony Operating Margin Regression Statistics

Arithmetic Mean(15.12)
Geometric Mean3.87
Coefficient Of Variation(81.23)
Mean Deviation11.52
Median(24.34)
Standard Deviation12.29
Sample Variance150.94
Range24.6676
R-Value0.84
Mean Square Error47.34
R-Squared0.71
Significance0.000045
Slope2.17
Total Sum of Squares2,264

Harmony Operating Margin History

2025 0.28
2023 0.33
2022 0.27
2021 0.22
2020 0.023

About Harmony Biosciences Financial Statements

Harmony Biosciences investors use historical fundamental indicators, such as Harmony Biosciences' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Harmony Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania. Harmony Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 180 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.